third-generation PCSK9 inhibitor today announced the publication of Phase 3 LIBerate-HoFH study of Lerodalcibep in a globally diverse homozygous familial hypercholesterolemia (HoFH) population was ...

PCSK9, which reduces LDL receptor recycling, is increased. E3-ubiquitin ligase inducible degrader of the LDL receptor has a similar function, but its role in familial hypercholesterolemia (FH ...

High cholesterol levels lead to plaque formation in arteries that restrict blood and oxygen flow. Familial ...

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...

Familial hypercholesterolemia (FH ... novel treatments like proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These new therapies can help achieve LDL-C goals more effectively ...

Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.

At the moment no oral PCSK9 drugs have started clinical development ... in development for patients with non-inherited forms of high cholesterol who can’t meet treatment targets with current ...

Taylor Tepper covered banking, investing and pretty much everything else in personal finance for more than a decade, with his work appearing in the New York Times, Fortune and MONEY magazine, as ...